Kaneq Pharma

Daniel Bouthillier  Ph.D. , MBA, CSPQ

President and CEO

Daniel Bouthillier is co-founder of Kaneq Pharma. He has over 20 years of experience in research administration. He was Executive Director of Research Administration and Planning for various Merck research sites in North America. He was also Executive Director for Merck Global Facilities Management with responsibilities for Canada, US sites, Asia Pacific and South America. In previous positions, Mr. Bouthillier was Senior Scientist and Administrator at the Clinical Research Institute of Montreal and also Head of Biochemistry at l’Hôtel-Dieu de Sorel and at Fleury Hospital in Montreal. He sits on many evaluation committees and boards such as Genome Quebec, Centre québécois de valorisation des biotechnologies, Biomod Concepts. Mr. Bouthillier received his Ph.D. in Clinical Sciences from the Université de Montréal and holds a certification in Clinical Biochemistry. He also completed an MBA at l’École des Hautes Commerciales in Montreal. 

Brian P. Kennedy, Ph.D.

Vice President, Biology


Dr. Kennedy received his Ph.D. in Biochemistry from Queen's University, Kingston, followed by Post-Doctoral training at the University of Calgary.  He joined Merck Frosst in 1989 and has worked on a number of successful programs, particularly on targets within the Arachidonic Acid Cascade including FLAP, PLA2 and Cox-2.  His major effort has been focused on Metabolic Disorders where he was responsible for the development of this research group and the oversight of the drug discovery efforts on programs including PTP-1B, SCD-1, Renin and novel target discovery.  Dr. Kennedy is the author of more than 80 scientific publications and is an inventor on 8 issued patents.  Prior to co-founding Kaneq Pharma, he served as a Senior Director in the Department of Biochemistry and Molecular Biology at the Merck Frosst Center for Therapeutic Research in Montreal, Canada.


Cameron Black, Ph.D.

Vice President, Discovery


Dr. Black holds a Ph.D in chemistry from Harvard University and has 18 years of drug discovery experience with Merck.  He has been responsible for the identification of seven development candidates during this time and also led teams responsible for the development of Previcox® and odanacatib, a cathepsin K inhibitor currently in Phase III development.  Dr Black is the author of more than 50 scientific publications and is an inventor on 25 issued patents.  Prior to co-founding Kaneq Pharma, he served as Director of Chemistry and Site Scientific Operations Lead at Merck Frosst.